TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Miradry Treatment for Focal Axillary Hyperhidrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~This study will recruit patients diagnosed with focal hyperhidrosis with a known diagnosis of primarily axillary localization.~We will only enroll patients available for both treatment visits. Availability for follow-up visit is optional.~Only patients between the ages of 18 and 29 years when the first HHIQ is administered will be eligible.~The upper age limit was so determined because patients over 29 years often present with psychopathology which is far more recalcitrant to correction of any kind regardless of effectiveness because of the duration of the condition.~The lower age limit was so determined because 18 years and up are the ages for which the miraDry ® procedure has been approved for use by the FDA.~All participants will be screened using the Hyperhidrosis Disease Severity Scale (HDSS).~Only patients reporting their condition as a 3 out of 4 or higher on the HDSS will be eligible for study because preliminary data suggests effective detection of psychological changes only at higher reported levels of sweating severity.~A patient's previous non-invasive treatment course, including but not limited to prescription of psychiatric medication and topical therapies, will not justify exclusion from this study.~Exclusion Criteria:~Patients who are unable to provide informed consent, have known allergies to lidocaine, hibiclens with 4% chlorhexidine, and/or epinephrine, are pregnant (as determined by self-reporting), are unable to take oral antibiotics or antiseptic washes, have heart pacemakers or other electronic device implants, and who need supplemental oxygen are not eligible to participate in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: f

Study Arms:
- MiraDry ® treatment (Type: EXPERIMENTAL): MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: S.E.S Shoulder Arthroplasty Data Collection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A pre-operative level of pain and function the same as for conventional joint replacement~* A likelihood of obtaining relief of pain and improved function~* Full skeletal maturity~* Ability to follow instructions~* Good general health for age~* Willing to return for follow-up evaluations~Exclusion Criteria:~* Glenohumeral joint infection, osteomyelitis~* Neuro-muscular complications~* Inability to co-operate with and complete the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- S.E.S prosthesis (Type: None): Consecutive series of patients with a S.E.S prosthesis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Playmaker 3D Printed Knee Extender

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14-60 years old patients who have suffered an isolated primary ACL rupture~Exclusion Criteria:~* Patients who have already attained full knee extension~* Open skin wounds that would come into contact with the device~* Pregnant women

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Experimental Arm (Type: EXPERIMENTAL): Participants will utilize a 3D printed knee extension device and an at-home prehabilitation program designed to be used with the 3D printed knee extension device.
- Control Arm (Type: OTHER): Participants will receive the standard prehabilitation education at Sanford and provided exercises to do at home.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women ≥ 18 years of age, at the time of signing the informed consent form (ICF).~2. Relapsed and/or primary refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) with subtype refractory anemia with excess blasts (RAEB)-2 defined as high or very high-risk that is recurrent or refractory, or the patient is intolerant to established therapy.~3. Subject consents to hospitalization for first (Cycle 1 Day 1) dose of CC-90002 and for 72 hours after.~4. Subject consents to serial bone marrow aspiration and biopsies as specified.~5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 2.~6. Eligible study subjects must exhibit acceptable liver, renal, and coagulation function as assessed by laboratory tests.~7. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and for up to 8 weeks following the last dose of CC 90002.~Exclusion Criteria:~1. Active central nervous system (CNS) leukemia or known CNS leukemia.~2. Immediately life-threatening, severe complications of leukemia.~3. Impaired cardiac function or clinically significant cardiac diseases.~4. Glucose-6-phosphate dehydrogenase (G6PD) deficiency.~5. Prior autologous hematopoietic stem cell transplant ≤ 3 months.~6. Prior allogeneic hematopoietic stem cell transplant (HSCT) with either standard or reduced intensity conditioning ≤ 6 months.~7. Systemic immunosuppressive therapy post HSCT or with clinically significant graft-versus-host disease (GVHD).~8. Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half lives or 4 weeks whichever is shorter.~9. Major surgery ≤ 2 weeks and recovered from any clinically significant effects of recent surgery.~10. Pregnant or nursing females.~11. Known HIV infection.~12. Known chronic hepatitis B or C (HBV/HCV) infection.~13. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants.~14. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia.~15. History of concurrent second cancers requiring active, ongoing systemic treatment.~16. Subjects for whom potentially curative anticancer therapy is available.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose escalation of CC-90002 (Type: EXPERIMENTAL): CC-90002 by intravenous (IV) infusion on a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prime Boost Vaccination Strategy Combining Conjugated Anti- Pneumococcal Vaccine (s0) and Polysaccharide Anti- Pneumococcal Vaccine (s4) Compared to Polysaccharide Anti- Pneumococcal Vaccine Alone (s4) In Patients With Common Variable Immunodeficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years and \< 65 years~* Common variable immunodeficiency according to the WHO criteria,~* Patients treated with intravenous or subcutaneous immunoglobulin.~* Written informed consent~* Absence of acute infections, or other evolutive diseases related to the (cancer, auto-immune disease...)~Exclusion Criteria:~* IgG subclass deficiency~* IgA selective deficiency,~* Other primary humoral deficiency (X-linked agammaglobulinemia, Hyper IgM syndrome),~* Long course treatment with corticosteroids \> 5mg per day~* Chemotherapy in the last 3 years,~* Prior pneumococcal vaccination in the last 2 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PPS (Type: ACTIVE_COMPARATOR): Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
- PnCJ PPS (Type: EXPERIMENTAL): Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AQUAVAN® Injection for Sedation in Elderly Patients Undergoing Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient provided signed/dated Informed Consent and HIPAA Authorization after receiving a full explanation of the extent and nature of the study.~2. Patient was at least 18 years of age at the time of screening.~3. Female patient must have been surgically sterile, postmenopausal, or not pregnant or lactating, and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predosing periods.~4. Patient met the American Society of Anesthesiologists (ASA) Physical Status Classification of I to III.~Exclusion Criteria:~1. Patient had a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic or benzodiazepine.~2. Patient did not meet nils per os (NPO) status per ASA Guideline or institution's guideline.~3. Patient had condition(s) that, in the opinion of the Investigator, could interfere with appropriate airway management.~4. Patient required artificial ventilation prior to the initiation of bronchoscopy or was admitted to the intensive care unit.~5. Patient had a history of mental or visual impairment that would not permit successful measurement of cognitive evaluations.~6. Patient was unwilling to adhere to pre- and postprocedural instructions.~7. The use of fentanyl or midazolam was contraindicated for the patient.~8. Patient had participated in an investigational study within 1 month prior to study start.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the pancreas~* Metastatic disease~* Received at least two prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease.~* At least one of the prior systemic cytotoxic chemotherapy regimens for unresectable, locally advanced or metastatic disease must have contained gemcitabine and have met the following criteria:~* Completed at least one cycle of the treatment~* Received gemcitabine administered at a minimum dose of 800 mg/m2 per week in the first cycle of treatment~* Progressed while receiving this gemcitabine regimen or within 3 months of completing gemcitabine~* Progression was documented,~* Preferentially radiologically by tumor growth or new lesions, or by~* Clear symptomatic deterioration supported by at least two of the following clinical criteria: ≥ 10% worsening in KPS or ≥ 1 worsening in ECOG; increasing weakness or fatigue; progressive weight loss; new/worsening pain requiring increased pain medication; new/worsening jaundice, nausea, or vomiting; new/worsening ascites or pleural effusions; other physical or laboratory findings consistent with disease progression.~* KPS \>/= 70~* Adequate bone marrow function~* Adequate hepatic function~* Adequate renal function~Exclusion Criteria:~* CNS metastatic disease~* Bulky disease (any single mass \>10 cm).~  -\>Grade 2 nausea or vomiting, and/or signs of intestinal obstruction.~* Prior external beam irradiation to a field that includes more than 30% of the red bone marrow.~* Patients with clinically significant severe cardiorespiratory disease.~Please consult with the clinical trial site for the full detailed list of specific inclusion/exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A IMMU-107 and gemcitabine (Type: EXPERIMENTAL): IMMU-107 and low dose gemcitabine
- Arm B Placebo and low dose gemcitabine (Type: ACTIVE_COMPARATOR): Placebo and low dose gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV positive~* Female~* Age 18-45~* Using any of the following medication regimens: no ARV medication, entry inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors, and CCR5 agonists. Acceptable NRTI combinations include zidovudine (ZDV), lamivudine (3TC), emtricitabine (FTC), didanosine (ddl), stavudine (d4T), abacavir (ABC), and tenofovir disoproxil fumarate (TDF)~* Ovulatory (mid-luteal progesterone \>3ng/dL)~* Not planning to conceive during the study period~* Willing to abstain from grapefruit products~* If taking ritonavir, willing to use alternate non-hormonal contraception~* BMI \< or = 40~* Able to consent in English or Spanish~* No change in medication regimen for at least 21 days prior to study entry and no planned change during the study period~* CD4 \> or =200, and/or not considered profoundly immuncompromised by primary HIV provider~Exclusion Criteria:~* Using on the combination of ZDV at d4T~* Platelets \<50,000~* AST or ALT \> twice upper limit of normal~* Bilirubin \> twice upper limit of normal~* Use of other CYP3A4 inducing or inhibiting medications~* Pregnant or breastfeeding in last 30 days~* Use of DepoProvera in last 180 days~* Use of any other hormonal contraception in last 30 days~* Undiagnosed vaginal bleeding or invasive cancer of the reproductive tract~  -\>50% change in tobacco use in the last month~* Initiation or titration of methadone therapy in the last month~* Uncontrolled thyroid disease~* Contraindication to estrogen use~* Inability to comply with study protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ritonavir (Type: EXPERIMENTAL): Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
- Control (Type: ACTIVE_COMPARATOR): Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written or verbal informed consent (IC) for participation in the study~* Subjects who completed 48 weeks of treatment according to the REFALS study protocol~* Able to swallow study treatment capsules at the time of completing 48 weeks dosing in the REFALS study~Exclusion Criteria:~* Development (or significant worsening from baseline of the REFALS study) of serious cardiovascular disease (e.g.: myocardial infarction, heart failure, arrhythmia, stroke, or second or third degree atrioventricular (AV) block)~* Pulse/heart rate repeatedly \>100 bpm after 5-minute rest at baseline. If the pulse/heart rate is \>100 bpm in the first recording, then a second recording must be done after another 5 min rest to confirm pulse/heart rate \>100 bpm~* Systolic blood pressure (SBP) \<90 mmHg~* Severe renal impairment (creatinine clearance \< 30ml/min or creatine \>170 µmol/l at 48 week visit of the REFALS study, or on dialysis~* Severe hepatic impairment at the discretion of the investigator~* Women of reproductive age without a negative pregnancy test and without a commitment to using a highly effective method of contraception (e.g.: oral hormonal contraceptive associated with inhibition of ovulation, intrauterine devices and long acting progestin agent), if sexually active during the study, and for 1 month after the last dose of the study treatment. Women who are postmenopausal (1 year since last menstrual cycle), surgically sterilised or who have undergone a hysterectomy are considered not to be reproductive and can be included~* Subject judged to be actively suicidal by the investigator~* Any other clinical significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results or constitute a health risk for the subject if he/she took part in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Levosimendan (Type: EXPERIMENTAL): Oral Levosimendan; Levosimendan 1mg capsules for oral administration, once to twice a day, continued as long as clinically beneficial. The total study duration is up to 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Utility of Exercise-induced N-terminal (NT) Pro-brain Natriuretic Peptide Levels in Predicting Prognosis in Asymptomatic Aortic Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. valvular AS (Doppler velocity ≥ 3.0 m/s)~2. no baseline symptoms referable to valvular heart disease~3. able to perform ETT~Exclusion Criteria:~1. more than mild aortic regurgitation, mitral regurgitation/ stenosis, or tricuspid regurgitation/stenosis~2. previous AVR~3. known coronary artery disease~4. creatinine clearance 50 mL/min~5. LVEF \< 50%~6. planned valve surgery prior to enrollment~7. significant pulmonary disease~8. unable to give informed consent~9. pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: OTHER): 10 patients with no aortic stenosis
- B (Type: OTHER): 100 patients with asymptomatic AS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older.~* Ulcerative colitis described according to usual criteria, diagnosed for at least 1 year.~* Oral maintenance treatment with 5-ASA only for at least 3 months with a dosage of 2 to 3 g/day.~* Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at inclusion.~* Signed informed consent form.~Exclusion Criteria:~* Patients allergic to aspirin or salicylates derivatives~* Patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of sulfasalazine, mesalazine or 4-ASA.~* Patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min.~* Patients with history or physical examination findings indicative of active alcohol or drug abuse.~* Women who are pregnant or nursing.~* Patients with a history of disease, including mental/emotional disorder that would interfere with their participation in the study.~* Patients who participated in another clinical study in the last 3 months.~* Patients who are unable to comply with the requirements of the protocol~* Female of childbearing potential without efficacious contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues